CD274 and neoplasm: Analogously, the role of LXR agonist-mediated cholesterol metabolism in immunosuppressive MDSCs could reverse un-responsive anti-PD-L1 immunotherapy, and elicit augmented or synergistic anti-tumor immune responses [94].